ASX:ATX

Amplia Therapeutics (ATX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ATX Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 77,249 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Amplia Therapeutics alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Amplia Therapeutics

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

ATX Stock News Headlines

February 14, 2024 | finance.yahoo.com

Amplia Therapeutics moves to next phase of pancreatic cancer treatment trial

January 18, 2024 | finance.yahoo.com

FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

August 22, 2023 | seekingalpha.com

GDTC CytoMed Therapeutics Limited

May 29, 2023 | finance.yahoo.com

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

May 22, 2023 | proactiveinvestors.com.au

Amplia secures funding to assess AMP945 topical applications

May 17, 2023 | investing.com

Amplia Therapeutics Ltd (ATX)

March 10, 2023 | uk.finance.yahoo.com

Amplia Therapeutics Limited (ATX.AX)

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 27, 2023 | finance.yahoo.com

Amplia Therapeutics CEO outlines 2023 milestones

See More Headlines

Receive ATX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amplia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:ATX
CUSIP: N/A
CIK: N/A
Web: www.ampliatx.com
Phone: 61 2 8003 3650
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($0.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,460,000.00
Net Margins: -238.69%
Pretax Margin: N/A
Return on Equity: -26.40%
Return on Assets: -14.40%

Debt

Debt-to-Equity Ratio: 15.18
Current Ratio: 3.43
Quick Ratio: 5.05

Sales & Book Value

Annual Sales: $1.87 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 4.88
Book Value: A$0.08 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 194,010,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.51

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Christopher J. Burns B.Sc. (Age 59)
BSc(Hons), Ph.D., CEO, MD & Director
Comp: $1.51M
Mr. Tim Luscombe B.Com.
C.A., Chief Financial Officer
Ms. Rhiannon Jones B.Sc.
Ph.D., Chief Operating Officer
Mr. Andrew John Cooke FAICS (Age 64)
FCIS, FGIA, L.L.B., LLB, MAICD, Company Secretary
Comp: $76.67k

Key Competitors

View All Competitors

Insiders

This page (ASX:ATX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Amplia Therapeutics (ATX) Stock Price, News & Analysis

About Amplia Therapeutics

ATX Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info